Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Mahamaya Lifescience IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2016 Industry: Pesticides & Agrochemicals Listed Page

Profile
Issue Size 50.47 Cr
Profile
Price Range 108  to  114 per share
Profile
Min Investment ₹114
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Our company specializes in the manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies, as well as multinational corporations (MNCs). We began our journey by focusing on import and registration of vital pesticide molecules (Technical) that were not produced domestically in India. We imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. After successful registration we marketed these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs. Read More

Basic Info

Face Value 10 per share

Price 108  to  114 per share

P/E (x) 15

Sales( Cr.) 264

PAT( Cr.) 13

EPS 7.6

Draft Prospectus

Exchange BSE-SME

Promoter

Company Promoters

Krishnamurthy Ganesan Prashant Krishnamurthy Lalitha Krishnamurthy

Pre Issue Share Holding 77.27%

Post Issue Share Holding 56.35%

Listing Details:

Listing Price: 116

Listing Gain: 1.72%

Current Price: 166

Gain On Issue: 166 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Nov 11, 2025
Closing Date Nov 13, 2025
Allotment Nov 14, 2025
Refund Nov 17, 2025
Delivery of Shares Nov 17, 2025
Listing Date Nov 18, 2025

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 2400 273,600
Retail (Max) -- -- --
S-HNI (Min) 1 2400 273,600
S-HNI (Max) 3 7200 820,800
B-HNI (Min) 4 9600 1,094,400

Objective of the Issue

a. Purchase of Equipment for existing Formulation plantb. Funding capital expenditure towards setting up of a new Technical manufacturing plant.c. Construction of Warehouse Building and Purchase of Machineryd. Funding working capital requirement of our Companye. General Corporate purposes

Issue

Category Nos Bid Bid (x)
QIB 1176000 1401600 1.2x
NII 1191600 3514800 2.9x
Retail 2059200 2107200 1x
EMP 0 0 0x
Total 4426800 7023600 1.6x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Mahamaya Lifescience Profit & Loss

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 90 137 162 264
Other Income 0 0 1 3
Total Income 90 137 163 267
Total Expenditure 84 128 148 241
Operating Profit 7 9 15 26
Interest 2 3 6 7
Depreciation 1 1 1 2
Exceptional Income / Expenses 0 0 0 0
Profit Before Tax 4 5 7 17
Provision for Tax 1 1 2 4
Profit After Tax 3 4 5 13
Adjustments 0 0 0 0
Profit After Adjustments 3 4 5 13
Adjusted Earnings Per Share 2 2.7 3.8 7.3

Mahamaya Lifescience Balance Sheet

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 16 19 25 49
Minority's Interest 0 0 0 0
Borrowings 10 10 9 6
Other Non-Current Liabilities 0 0 1 1
Total Current Liabilities 30 48 78 132
Total Liabilities 56 78 112 188
Fixed Assets 18 20 20 26
Other Non-Current Assets 4 4 4 5
Total Current Assets 33 54 87 157
Total Assets 56 78 112 188

Mahamaya Lifescience Cash Flow

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 1 1 1
Cash Flow from Operating Activities 2 1 -23 1
Cash Flow from Investing Activities -3 -3 -2 -8
Cash Flow from Financing Activities 1 2 24 9
Net Cash Inflow / Outflow 0 1 -0 1
Closing Cash & Cash Equivalent 1 1 1 2

Mahamaya Lifescience Ratios

# Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 1.98 2.73 3.8 7.29
CEPS(Rs) 2.68 3.66 4.88 8.28
DPS(Rs) 0 0 0 0
Book NAV/Share(Rs) 11.43 14.15 17.95 27.82
Core EBITDA Margin(%) 7.05 6.66 8.34 8.8
EBIT Margin(%) 6.25 5.97 8.2 9.27
Pre Tax Margin(%) 4.14 3.72 4.41 6.57
PAT Margin (%) 3.03 2.74 3.23 4.9
Cash Profit Margin (%) 4.1 3.66 4.15 5.57
ROA(%) 4.9 5.62 5.49 8.62
ROE(%) 17.34 21.34 23.67 34.94
ROCE(%) 16.12 20.81 21.52 26.23
Receivable days 36.97 24.81 42.74 53.04
Inventory Days 75.64 71.11 96.92 104.49
Payable days 82.67 69.44 67.49 64.91
PER(x) 0 0 0 0
Price/Book(x) 0 0 0 0
Dividend Yield(%) 0 0 0 0
EV/Net Sales(x) 0.21 0.16 0.33 0.27
EV/Core EBITDA(x) 2.89 2.39 3.59 2.74
Net Sales Growth(%) 0 52.45 17.87 63.49
EBIT Growth(%) 0 45.57 61.81 84.96
PAT Growth(%) 0 37.72 39.14 148.02
EPS Growth(%) 0 37.72 39.14 91.77
Debt/Equity(x) 1.22 1.25 2.22 1.18
Current Ratio(x) 1.11 1.13 1.12 1.19
Quick Ratio(x) 0.5 0.41 0.47 0.44
Interest Cover(x) 2.96 2.65 2.16 3.43
Total Debt/Mcap(x) 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 63% 43% 0% 0%
Operating Profit CAGR 73% 55% 0% 0%
PAT CAGR 160% 63% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 35% 27% 24% 24%
ROCE Average 26% 23% 21% 21%

Company Contact Information

Mahamaya Lifesciences Ltd.

Shilpi Bhardwaj

+91-1146561474

s@mahamayalifesciences.com

Unit No: D P T – 033 Ground Floor, Plot No: 79 – 80, Dlf Prime Tower F – Block, Okhla, Phase – 1

IPO Lead Manager(s)

Mahamaya Lifesciences Ltd.

Oneview Corporate Advisors Pvt Ltd.

Registrar Info

Mahamaya Lifesciences Ltd.

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District, Nanakramguda Hyderabad – 500032 Tel. No. 040 67161500 Fax. No. 040 23001153 E-mail: einward.ris@karvy.com Website: www.karvy.com Toll Free No. of exclusive Call Centre:1-800-345001

040 - 67162222/18003094001

einward.ris@kfintech.com

https://www.kfintech.com

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!